While eye drops remain the most common treatment due to affordability, they suffer from poor bioavailability, low retention time, and high rates of patient non-compliance. Advanced systems like biodegradable implants and drug-eluting contact lenses are being developed to provide sustained drug release and better therapeutic efficacy.
Drug-eluting contact lenses are emerging as the fastest-growing platform. They represent a paradigm shift in non-invasive delivery, offering continuous drug release for chronic disorders where daily compliance with eye drops is a challenge.
Nanotechnology is used to create nano-formulations, such as nanomicelles and injectable particulate systems, which enhance the solubility and corneal penetration of drugs. For example, Santen recently launched a nanomicelle-based formulation to improve treatment for ocular surface disorders.
North America currently leads the market due to its advanced clinical infrastructure and high R&D investment. However, the Asia-Pacific region is the fastest-growing market, driven by a large patient base, increasing urbanisation, and government focus on preventing blindness in countries like China and India.
In 2024, Alcon launched a next-generation biodegradable implant for glaucoma, and Johnson & Johnson Vision expanded clinical trials for drug-eluting contact lenses. Additionally, Ocular Therapeutix received FDA approval for a pediatric expansion of its DEXTENZA insert in 2023.
The market is seeing a convergence of digital health and drug delivery through "smart" devices. An example includes smart contact lenses that can monitor intraocular pressure while simultaneously delivering pharmaceuticals to treat chronic eye conditions.
Hospitals maintain leadership as the primary end users. They are better equipped to administer advanced therapies, such as intravitreal implants and intracanalicular inserts, which require trained healthcare professionals and surgical or post-surgical settings.
The market utilizes various materials including biodegradable polymers (PLGA, Collagen, Hydrogels) and liposomes. Production technologies include 3D printing, electrospinning, extrusion, and micro patterning to create precise delivery mechanisms like microneedle arrays and episcleral implants.
The industry faces high production and infrastructure costs, which may limit the entry of smaller players. Additionally, supply chain vulnerabilities regarding raw materials—specifically biotech polymers and nanotechnology components—pose long-term risks to scaling these advanced systems.
